BioTime Inc. (BTX)

0.92
AMEX : Health Technology
Prev Close 0.99
Day Low/High 0.90 / 0.97
52 Wk Low/High 0.66 / 2.61
Avg Volume 459.10K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 148.15M
EPS -0.40
P/E Ratio 4.60
Div & Yield N.A. (N.A)
BioTime Announces Issuance Of 14 Patents In The Fields Of Regenerative Medicine, And Cancer Diagnosis And Therapy

BioTime Announces Issuance Of 14 Patents In The Fields Of Regenerative Medicine, And Cancer Diagnosis And Therapy

BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies.

BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million In Equity Financing

BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million In Equity Financing

BioTime, Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias Biotherapeutics, Inc.

BioTime Subsidiary Asterias Biotherapeutics Announces Investment By CEO

BioTime Subsidiary Asterias Biotherapeutics Announces Investment By CEO

BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro Lichtinger, President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc.

BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger As President And Chief Executive Officer

BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger As President And Chief Executive Officer

BioTime, Inc. (NYSE MKT: BTX) today announced that Pedro Lichtinger has been appointed President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc.

BioTime To Present At The Jefferies 2014 Global Healthcare Conference

BioTime To Present At The Jefferies 2014 Global Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime’s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings

BioTime’s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc.

BioTime Receives ISO 13485 Certification For Medical Devices

BioTime Receives ISO 13485 Certification For Medical Devices

BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem ® ...

BioTime’s Subsidiary OncoCyte Corporation And Cornell University Enter License Agreement To Accelerate Lung Cancer Diagnostic Product Development

BioTime’s Subsidiary OncoCyte Corporation And Cornell University Enter License Agreement To Accelerate Lung Cancer Diagnostic Product Development

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a License Agreement with Cornell University through which Weill Cornell Medical College will provide...

Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com

Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com

Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

Asterias Biotherapeutics, Inc. To Present Phase I Clinical Data At The 17th Annual Meeting Of The American Society Of Gene & Cell Therapy

Asterias Biotherapeutics, Inc. To Present Phase I Clinical Data At The 17th Annual Meeting Of The American Society Of Gene & Cell Therapy

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc.

BioTime Announces First Quarter 2014 Results And Recent Developments

BioTime Announces First Quarter 2014 Results And Recent Developments

BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the first quarter ended March 31, 2014 and highlighted recent corporate accomplishments.

LifeMap Solutions, Inc. To Develop Mobile Health Products With Mount Sinai’s Icahn School Of Medicine

LifeMap Solutions, Inc. To Develop Mobile Health Products With Mount Sinai’s Icahn School Of Medicine

BioTime, Inc. (NYSE MKT:BTX) announced today that its subsidiary LifeMap Sciences, Inc.

BioTime Raises $6.4 Million In Equity Financing

BioTime Raises $6.4 Million In Equity Financing

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately $6.

BioTime To Present At GTC Stem Cell Summit 2014

BioTime To Present At GTC Stem Cell Summit 2014

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime, Inc. Announces Board Membership Changes And Management And Board Changes At Its Subsidiary Asterias Biotherapeutics, Inc.

BioTime, Inc. Announces Board Membership Changes And Management And Board Changes At Its Subsidiary Asterias Biotherapeutics, Inc.

BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors.

BioTime To Present At 13th Annual Needham Healthcare Conference

BioTime To Present At 13th Annual Needham Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime To Present At Regen Med Investor Day March 26 In New York

BioTime To Present At Regen Med Investor Day March 26 In New York

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Announces Fourth Quarter And Fiscal Year End 2013 Financial Results And Recent Corporate Accomplishments

BioTime Announces Fourth Quarter And Fiscal Year End 2013 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

BioTime Raises $3.5 Million Through Preferred Stock Offering

BioTime Raises $3.5 Million Through Preferred Stock Offering

BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.

BioTime Provides Financing And Product Development Update

BioTime Provides Financing And Product Development Update

BioTime, Inc. (NYSE MKT: BTX) today announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering facility, and through sales of BioTime common shares...

Top Insider Trades: TWI CYTK CLFD BTX

Top Insider Trades: TWI CYTK CLFD BTX

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

BioTime CEO Dr. Michael West To Present At 9th Annual Stem Cell Summit

BioTime CEO Dr. Michael West To Present At 9th Annual Stem Cell Summit

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development Of Bladder Cancer Diagnostics In The United States And China

BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development Of Bladder Cancer Diagnostics In The United States And China

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

BioTime Reports Results Of Clinical Safety Trial Of Renevia™

BioTime Reports Results Of Clinical Safety Trial Of Renevia™

BioTime, Inc. (NYSE MKT: BTX) today announced the completion of a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, and the...

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are snapping up shares.

Top Insider Trades: BTX TTGT OFG ACCL

Top Insider Trades: BTX TTGT OFG ACCL

The top 10 open-market insider purchases and sales filed at the SEC Monday.